Pre-Clinical Programs

Biokine Announces Issuance of European Patent

Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

January 20th, 2015|Pre-Clinical Programs, Recent News|

Biokine Announces Issuance of Mexican Patent

Biokine Therapeutics Announces Issuance of Mexican Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

January 19th, 2015|Pre-Clinical Programs, Recent News|

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of peptides for inhibiting chemokine binding to chemokine receptors

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of peptides for inhibiting chemokine binding to chemokine receptors (BKT130 Project).

August 5th, 2014|Pre-Clinical Programs|

Biokine Therapeutics Announces Issuance of Japanese Patent covering the composition and use of polypeptides

Biokine Therapeutics Announces Issuance of Japanese Patent covering the composition and use of polypeptides

July 2nd, 2014|Pre-Clinical Programs|

Patent issued in Japan covering the composition and use of novel chemokine binding polypeptides

Biokine Therapeutics Announces Issuance of Japan Patent covering the composition and use of novel chemokine binding polypeptides
capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

July 1st, 2014|Pre-Clinical Programs, Recent News|

Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides

Biokine Therapeutics Announces Issuance of Chinese Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

June 30th, 2014|Pre-Clinical Programs|

Biokine Therapeutics Announces Issuance of United States Patent covering the use of CXCR4 antagonist for wound healing

Biokine Therapeutics Announces Issuance of United States Patent covering the use of CXCR4 antagonist for wound healing and re-epithelialization (BKT170 Project).

April 12th, 2014|Pre-Clinical Programs|

Biokine Therapeutics Announces Issuance of United States Patent

Biokine Therapeutics Announces Issuance of United States Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

January 29th, 2014|Pre-Clinical Programs|

European Patent issued covering the composition and use of novel chemokine

Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel
chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

January 11th, 2014|Pre-Clinical Programs|